Drug and alcohol dependence acute effects of pod-style e-cigarettes in vaping-naïve smokers.
E-cigarette
Nicotine formulation
Smoking
Switching
Journal
Drug and alcohol dependence
ISSN: 1879-0046
Titre abrégé: Drug Alcohol Depend
Pays: Ireland
ID NLM: 7513587
Informations de publication
Date de publication:
01 11 2021
01 11 2021
Historique:
received:
16
02
2021
revised:
01
09
2021
accepted:
04
09
2021
pubmed:
3
10
2021
medline:
15
12
2021
entrez:
2
10
2021
Statut:
ppublish
Résumé
This study investigated the acute effects of exposure to pod-style e-cigarettes on subjective, behavioral, and physiological outcomes indicative of the potential to encourage vaping-naïve smokers to switch to e-cigarettes. In a within-subject experiment, never-vaping adult smokers interested in trying e-cigarettes (n = 24) completed 4 laboratory visits following 16-hr tobacco abstinence. Visits involved controlled puffing from preferred brand cigarettes (OwnCig) or a standardized pod-style e-cigarette with either no nicotine (NoNic), nicotine freebase (NicFreebase; 0.5% nicotine concentration), or nicotine salt (NicSalt E-Cig; 2.8% concentration) solutions. Outcomes included smoking urge, mood, user experience, plasma nicotine, and a behavioral task assessing ability to delay smoking. NoNic, NicFreebase, and NicSalt pod-style e-cigarettes were significantly less effective than OwnCig at reducing smoking urge and increasing plasma nicotine, positive affect, satisfying user experience ratings, and ability to delay smoking on the behavioral task. Differences among pod-style e-cigarette conditions were limited to: (a) NicFreebase (vs. NoNic) preferentially suppressed participants' urge to smoke to alleviate negative mood, (b) NicFreebase (vs. NicSalt) slightly preferentially increased plasma nicotine; and (c) NicFreebase and NicSalt (vs. NoNic) produced higher aversive user experience ratings. In tobacco deprived smokers' initial vaping experience, controlled administration of certain pod-style e-cigarettes with 0.5% NicFreebase or 2.8% NicSalt may be deficient comparators to cigarettes in terms of their capacity to acutely improve mood, deliver nicotine, suppress smoking motivation, and offer a satisfying user experience. Future research is needed to test pod-style e-cigarettes with higher nicotine doses and confirm whether NicFreebase vs. NicSalt enhances nicotine absorption.
Sections du résumé
BACKGROUND
This study investigated the acute effects of exposure to pod-style e-cigarettes on subjective, behavioral, and physiological outcomes indicative of the potential to encourage vaping-naïve smokers to switch to e-cigarettes.
METHODS
In a within-subject experiment, never-vaping adult smokers interested in trying e-cigarettes (n = 24) completed 4 laboratory visits following 16-hr tobacco abstinence. Visits involved controlled puffing from preferred brand cigarettes (OwnCig) or a standardized pod-style e-cigarette with either no nicotine (NoNic), nicotine freebase (NicFreebase; 0.5% nicotine concentration), or nicotine salt (NicSalt E-Cig; 2.8% concentration) solutions. Outcomes included smoking urge, mood, user experience, plasma nicotine, and a behavioral task assessing ability to delay smoking.
RESULTS
NoNic, NicFreebase, and NicSalt pod-style e-cigarettes were significantly less effective than OwnCig at reducing smoking urge and increasing plasma nicotine, positive affect, satisfying user experience ratings, and ability to delay smoking on the behavioral task. Differences among pod-style e-cigarette conditions were limited to: (a) NicFreebase (vs. NoNic) preferentially suppressed participants' urge to smoke to alleviate negative mood, (b) NicFreebase (vs. NicSalt) slightly preferentially increased plasma nicotine; and (c) NicFreebase and NicSalt (vs. NoNic) produced higher aversive user experience ratings.
CONCLUSIONS
In tobacco deprived smokers' initial vaping experience, controlled administration of certain pod-style e-cigarettes with 0.5% NicFreebase or 2.8% NicSalt may be deficient comparators to cigarettes in terms of their capacity to acutely improve mood, deliver nicotine, suppress smoking motivation, and offer a satisfying user experience. Future research is needed to test pod-style e-cigarettes with higher nicotine doses and confirm whether NicFreebase vs. NicSalt enhances nicotine absorption.
Identifiants
pubmed: 34600262
pii: S0376-8716(21)00578-0
doi: 10.1016/j.drugalcdep.2021.109083
pmc: PMC8631487
mid: NIHMS1744608
pii:
doi:
Substances chimiques
Pharmaceutical Preparations
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
109083Subventions
Organisme : NIDA NIH HHS
ID : K24 DA048160
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA180905
Pays : United States
Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.
Références
JAMA Netw Open. 2021 Jan 4;4(1):e2032757
pubmed: 33433597
JAMA Netw Open. 2019 Nov 1;2(11):e1915494
pubmed: 31730180
J Pers Soc Psychol. 1988 Jun;54(6):1063-70
pubmed: 3397865
Psychopharmacology (Berl). 2021 Mar;238(3):825-831
pubmed: 33270145
Biometrics. 1988 Dec;44(4):1049-60
pubmed: 3233245
Intern Emerg Med. 2019 Sep;14(6):853-861
pubmed: 30712148
Addiction. 2014 Nov;109(11):1801-10
pubmed: 25078252
Addict Biol. 2009 Jan;14(1):99-107
pubmed: 18855800
Pulm Pharmacol Ther. 2007;20(4):355-64
pubmed: 17137814
J Appl Physiol (1985). 2020 Apr 1;128(4):1056-1058
pubmed: 31854246
Harm Reduct J. 2018 Jun 28;15(1):33
pubmed: 29954412
Expert Opin Drug Deliv. 2020 Dec;17(12):1727-1736
pubmed: 32842785
Addiction. 2019 Oct;114(10):1842-1848
pubmed: 31140666
Nicotine Tob Res. 2001 Feb;3(1):7-16
pubmed: 11260806
Tob Control. 2016 Nov;25(Suppl 2):ii81-ii87
pubmed: 27633767
J Abnorm Psychol. 2015 Aug;124(3):623-34
pubmed: 25961814
Psychol Addict Behav. 2015 Mar;29(1):71-81
pubmed: 25243836
Drug Alcohol Depend. 2016 Nov 01;168:176-180
pubmed: 27676583
Addict Behav. 2007 May;32(5):912-23
pubmed: 16875787
Biol Mass Spectrom. 1991 May;20(5):247-52
pubmed: 1883864
Nicotine Tob Res. 2020 Jun 12;22(7):1239-1243
pubmed: 31821492
Nicotine Tob Res. 2021 May 24;23(6):947-955
pubmed: 33486526
Exp Clin Psychopharmacol. 2013 Aug;21(4):269-76
pubmed: 23834551
Addiction. 2020 Dec;115(12):2197-2199
pubmed: 32307739
Nicotine Tob Res. 2021 Oct 7;23(11):1821-1830
pubmed: 34002223
Br J Addict. 1991 Sep;86(9):1119-27
pubmed: 1932883
Drug Alcohol Depend. 2019 Oct 1;203:1-7
pubmed: 31386973
Drug Alcohol Depend. 2020 Dec 1;217:108395
pubmed: 33176942
Am J Health Behav. 2021 May 1;45(3):443-463
pubmed: 33894794
JAMA Netw Open. 2020 Oct 1;3(10):e2020694
pubmed: 33048127
Int J Environ Res Public Health. 2017 Jun 16;14(6):
pubmed: 28621763
Nicotine Tob Res. 2020 Apr 21;22(5):791-797
pubmed: 31403695
Tob Control. 2020 Feb 10;:
pubmed: 32041833
Tob Control. 2020 Nov;29(6):679-686
pubmed: 31852818
N Engl J Med. 2018 Sep 20;379(12):1099-1102
pubmed: 30134127
J Chromatogr. 1981 Jan 2;222(1):61-70
pubmed: 6783675